news
Synthetic proteins key to modular nanoparticle design
Researchers have been able to customise nanoparticles to target biological entities, like tumours and viruses.
List view / Grid view
Drug Targets
A drug target is anything within a living organism to which a drug is directed and/or binds, resulting in a change in its behaviour or function.
news
Mechanism that triggers dendritic elongation discovered
Short-chain fatty acids produced by intestinal bacteria initiate dendritic elongation, a mechanism that could be used as a drug target.
news
Protein found to control breast cancer metastasis
Scientists have discovered the motor protein dynein commands movement of cancer cells in soft tissue models, offering new clinical targets.
news
New molecule disrupts pathways that promote cancer growth
Researchers have discovered a molecule that binds to a cancer cell protein, stopping growth of breast and ovarian tumours.
news
Pulmonary ionocytes: unexpected discovery has implications for CF
Researchers found surprising function of pulmonary ionocytes which may affect how cystic fibrosis drugs work.
article
Microbiotica: transforming medicine with microbiome magic
In this interview, Anne Neville, Director at Microbiotica, elaborates on the significance of the Microbiotica Culture Collection (MCC) and Microbiotica Reference Genome Database (MRGD), which are fundamental to the development of live biotherapeutic medicines.
article
Emotional scars: stigma with female adult acne
New research presented at the European Academy of Dermatology and Venereology (EADV) Congress 2023 in Berlin, Germany, has highlighted a previously underestimated aspect of acne's impact on individuals: its profound influence on social perception.
article
Patient-derived organoids in disease modelling
In an exclusive interview with Nikki Carter at Molecular Devices, we explore the the power of patient-derived organoids (PDOs) in drug discovery.
![In experiments in rats and mice, two Johns Hopkins scientists -- an engineer and an ophthalmologist -- report the successful use of nanoparticles to deliver gene therapy for blinding eye disease. A uniquely engineered large molecule allows researchers to compact large bundles of therapeutic DNA to be delivered into the cells of the eye [credit: John Hopkins Medicine].](https://www.drugtargetreview.com/wp-content/uploads/nanoparticle-gene-therapy-blindness-image.jpg)
article
Possible adulticidal drugs for Onchocerca volvulus
This article discusses the need for adulticidal drugs to treat Onchocerca volvulus infections, a parasite causing onchocerciasis (river blindness), as the current treatment with ivermectin and surgery presents challenges for affected communities. It highlights research findings on the potential of analgesic medicines to target adult worms and emphasises the importance…
article
Addressing increasingly resistant drugs by infectious agents
Infectious agents' drug resistance is a complex challenge affecting survival. Understanding their mechanisms in vectors, the potential of plant-derived treatments, and roles of nucleic acids and biochemical compounds is crucial for effective therapy, requiring collaborative international research through the One Health Initiative.
news
Conversations about the NHS: a bold prescription for it’s future
As the NHS celebrates its 75th anniversary, healthcare leaders, policymakers, and practitioners have been sharing their innovative ideas on how to reshape and safeguard its future.
webinar
SH2 domains as a target class in cancer and inflammation
25 July 2023 | By Eurofins Discovery
New SH2 domain binding assays developed by Eurofins Discovery have been launched to support drug discovery initiatives in the protein-protein interaction space and in targeted protein degradation. We present small molecule case study data for important targets within this target class including STAT Transcription factors and Kinases.
article
Targeted protein degradation: turning undruggable targets into druggable targets
Targeted protein degradation (TPD) is a cutting-edge approach in drug discovery that offers a more precise and efficient way to alter cellular pathways, offering the capability to convert 'undruggable targets' into 'druggable targets.' In this article, Drug Target Review’s Izzy Wood interviewed Astellas’ Masahiko Hayakawa, Head of Targeted Protein Degradation,…
article
The promise of iPSC-based multi-cell therapeutics
Drug Target Review’s Taylor Mixides exclusively interviews Matt Angel, PhD, Chief Executive Officer and President of Eterna Therapeutics, about a potential new class of cell therapies that may play an important role in the development of new cancer treatments.
article
The evolution and promise of gene therapies
Dr David Baram from gene therapy company EmendoBio provides a snapshot of the history of therapeutic genetic engineering.